BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.2.2.1//EN TZID:Asia/Jerusalem X-WR-TIMEZONE:Asia/Jerusalem BEGIN:VEVENT UID:1262@biology.technion.ac.il DTSTART;TZID=Asia/Jerusalem:20250108T130000 DTEND;TZID=Asia/Jerusalem:20250108T140000 DTSTAMP:20250101T095815Z URL:https://biology.technion.ac.il/en/seminars/phd-graduate-seminar-adi-sh apira/ SUMMARY:PhD Graduate Seminar- Dr. Adi Shapira [No Categories] DESCRIPTION:Location: Biology auditorium and by ZOOM:https://technion.zoom. us/j/91700637178 Adi Shapira\n Affiliation: \n Host:Prof. Reiter Yoram\n  \;\n\nTCR-like Antibodies for B Cell Malignancies. Can They Overcome Resistance to Antibody-Based CAR T Cells?\n\nChimeric antigen receptor (CA R) T cells directed at the CD19 surface protein are an effective treatment for refractory B cell  leukemia and lymphoma.\n\nDespite high response r ates\, many patients will experience relapse with loss of CD19 at the time of relapse\n\nTCR-like (TCRL) antibodies are designed to bind a peptides presented in the context of an HLA molecule\, and therefore expand the tar get repertoire of tumor associated antigens to include intra-cellular prot eins. In this study we aimed to address the phenomenon of CD19 negative re lapse following CAR T cell therapy using the TCRL approach. We have succes sfully isolated TCRL antibodies with specific binding to a complex of HLA- A2 and CD19-derived peptides.  TCRL-based CARs were generated and exhibit ed effective killing of multiple B cell malignancies\, including cells wit h loss of surface CD19. This study provides proof-of- concept for the targ eting of HLA-peptide complex using TCRL based therapies as means to overco me resistance to conventional CAR T cell therapy. LOCATION:Biology auditorium and by ZOOM:https://technion.zoom.us/j/91700637 178 END:VEVENT BEGIN:VTIMEZONE TZID:Asia/Jerusalem X-LIC-LOCATION:Asia/Jerusalem BEGIN:STANDARD DTSTART:20241027T010000 TZOFFSETFROM:+0300 TZOFFSETTO:+0200 TZNAME:IST END:STANDARD END:VTIMEZONE END:VCALENDAR